DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

[Usefulness of perospirone for the prevention of nausea related to opioid administration]

Author(s): Yomiya K, Matsuo N, Okuyama S

Affiliation(s): Department of Palliative Care, Saitama Cancer Center.

Publication date & source: 2008-04, Gan To Kagaku Ryoho., 35(4):625-8.

Publication type: English Abstract

PURPOSE: In our department, prochlorperazine, a D2 receptor antagonist, was previously administered to prevent nausea related to the introduction of opioids. However, we always had to consider extrapyramidal symptoms. Since August 2006, perospirone has been administered to all patients who have commenced oral opioid therapy, to prevent nausea. In this study, we investigated its usefulness in the prevention of nausea. METHODS: Perospirone (4 or 8 mg, once a day) was combined in all patients in whom opioid therapy was introduced with oxycodone at 10 mg/day. We retrospectively examined the presence or absence of nausea within 1 week. RESULTS: Oxycodone-related nausea occurred in 1 of 25 patients. There were no adverse reactions such as extrapyramidal symptoms. CONCLUSION: These results suggest the usefulness of perospirone for the prevention of nausea related to the intro- duction of opioids.

Page last updated: 2008-06-22

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017